TLPH · Insider Trading
Talphera, Inc. Common Stock
Every open-market purchase and sale reported by TLPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Marina Bozilenko | Director | A | +5,100 | — |
| 2026-06-24 | Joseph Todisco | Director | A | +5,100 | — |
| 2026-06-24 | Mark A Wan | Director | A | +5,100 | — |
| 2026-06-24 | Jill Marie Broadfoot | Director | A | +5,100 | — |
| 2026-06-24 | Stephen J Hoffman | Director | A | +5,100 | — |
| 2026-06-24 | Abhinav Jain | Director | A | +5,100 | — |
| 2026-06-24 | Adrian Adams | Director | A | +5,100 | — |
| 2026-05-21 | Shakil Aslam | Chief Medical Officer | F | −4,518 | −$3.72K |
| 2026-04-03 | Shakil Aslam | Chief Medical Officer | F | −2,118 | −$1.53K |
| 2026-04-03 | Raffi Asadorian | Chief Financial Officer | F | −2,444 | −$1.77K |
| 2026-04-03 | Badri N Dasu | Chief Engineering Officer | F | −2,444 | −$1.77K |
| 2026-04-03 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | F | −9,938 | −$7.18K |
| 2026-03-25 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | +213,310 | +$125.00K |
| 2026-03-17 | Wilmot B. Harkey | 10%+ Owner | A | +12,798,633 deriv. | — |
| 2026-02-20 | Raffi Asadorian | Chief Financial Officer | MIXED | +41,109 | +$33.43K |
| 2026-02-20 | Shakil Aslam | Chief Medical Officer | Buy | +35,000 | +$28.43K |
| 2026-02-20 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | MIXED | +92,626 | +$75.35K |
| 2026-02-20 | Badri N Dasu | Chief Engineering Officer | MIXED | +31,873 | +$25.92K |
| 2025-10-24 | Adrian Adams | Director | A | +4,267 | — |
| 2025-10-24 | Abhinav Jain | Director | A | +4,267 | — |
| 2025-10-24 | Jill Marie Broadfoot | Director | A | +4,267 | — |
| 2025-10-24 | Marina Bozilenko | Director | A | +4,267 | — |
| 2025-10-24 | Mark A Wan | Director | A | +4,267 | — |
| 2025-10-24 | Stephen J Hoffman | Director | A | +4,267 | — |
| 2025-10-16 | Joseph Todisco | Director | A | +6,397 | — |
| 2025-05-21 | Shakil Aslam | Chief Medical Officer | F | −4,517 | −$2.33K |
| 2025-04-03 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | MIXED | +274,310 | +$125.00K |
| 2025-04-03 | Badri N Dasu | Chief Engineering Officer | A | +15,000 | — |
| 2025-04-03 | Raffi Asadorian | Chief Financial Officer | A | +15,000 | — |
| 2025-04-03 | Shakil Aslam | Chief Medical Officer | A | +15,000 | — |
| 2025-04-02 | Daniel Mack | 10%+ Owner | A | +12,798,633 deriv. | — |
| 2025-02-26 | Shakil Aslam | Chief Medical Officer | Buy | +5,695 | +$6.04K |
| 2025-02-18 | Raffi Asadorian | Chief Financial Officer | F | −3,245 | −$2.17K |
| 2025-02-18 | Badri N Dasu | Chief Engineering Officer | F | −2,644 | −$1.77K |
| 2025-02-18 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | F | −10,575 | −$7.09K |
| 2025-02-12 | Raffi Asadorian | Chief Financial Officer | F | −2,119 | −$1.32K |
| 2025-02-12 | Badri N Dasu | Chief Engineering Officer | F | −1,759 | −$1.10K |
| 2025-02-12 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | F | −7,032 | −$4.39K |
| 2024-12-06 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | +5,000 | +$3.20K |
| 2024-12-02 | Raffi Asadorian | Chief Financial Officer | Sell | −155 | −$119 |
| 2024-12-02 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | +5,000 | +$3.65K |
| 2024-09-03 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | +7,260 | +$7.60K |
| 2024-06-24 | Mark A Wan | Director | A | +2,174 | — |
| 2024-06-24 | Adrian Adams | Director | A | +2,174 | — |
| 2024-06-24 | Abhinav Jain | Director | A | +2,174 | — |
| 2024-06-24 | Stephen J Hoffman | Director | A | +2,174 | — |
| 2024-06-24 | Marina Bozilenko | Director | A | +2,174 | — |
| 2024-06-24 | Jill Marie Broadfoot | Director | A | +2,174 | — |
| 2024-06-14 | Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | Buy | +10,000 | +$9.86K |
| 2024-03-21 | Wilmot B. Harkey | 10%+ Owner | J | +974,025 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel Mack | 10%+ Owner | 1,992,519 | $2.13M |
| Vincent J. Angotti | CHIEF EXECUTIVE OFFICER | 790,767 | $846.12K |
| Raffi Asadorian | Chief Financial Officer | 85,879 | $91.89K |
| Shakil Aslam | Chief Medical Officer | 76,542 | $81.90K |
| Badri N Dasu | Chief Engineering Officer | 71,440 | $76.44K |
| Adrian Adams | Director | 22,709 | $24.30K |
| Marina Bozilenko | Director | 14,147 | $15.14K |
| Stephen J Hoffman | Director | 13,959 | $14.94K |
| Mark A Wan | Director | 13,959 | $14.94K |
| Jill Marie Broadfoot | Director | 13,647 | $14.60K |
| Abhinav Jain | Director | 12,412 | $13.28K |
| Joseph Todisco | Director | 11,497 | $12.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TLPH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.